Solta Medical, Inc. (SLTM) Receives 501k Clearance from FDA for Clear + Brilliant Treatment
Solta Medical reported today reception of FDA 501k clearance for the Company’s Clear + Brilliant treatment, which had previously received CE mark and is based on SLTM’s fractional laser technology. The Clear + Brilliant treatment will be officially launched at the upcoming World Congress of Dermatology in Seoul, Korea. The advent of this new treatment would not have been possible without the Company’s mastery of fractional laser applications, as evident in SLTM’s Fraxel® treatment, which delivers minimally invasive clinical solutions for resurfacing aging/sun damaged skin. The Company started shipping the product to select/key international markets back in April and has…